Equities Analysts Offer Predictions for AVBP FY2027 Earnings

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Research analysts at HC Wainwright issued their FY2027 earnings per share estimates for ArriVent BioPharma in a report issued on Monday, August 17th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($4.24) for the year. HC Wainwright has a “Buy” rating and a $47.00 price target on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($3.96) per share.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.06).

Other equities analysts have also issued research reports about the stock. Truist Financial raised their price objective on shares of ArriVent BioPharma from $43.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, May 29th. Guggenheim reiterated a “buy” rating and set a $45.00 target price on shares of ArriVent BioPharma in a research report on Thursday, August 13th. BTIG Research reiterated a “buy” rating and issued a $42.00 target price on shares of ArriVent BioPharma in a research note on Thursday, August 13th. Citigroup decreased their price target on ArriVent BioPharma from $43.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ArriVent BioPharma in a research report on Friday, May 22nd. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.86.

ArriVent BioPharma Stock Performance

Shares of AVBP opened at $29.01 on Tuesday. The company has a market capitalization of $1.35 billion, a PE ratio of -8.01 and a beta of 1.36. The company’s 50 day moving average price is $31.76 and its 200 day moving average price is $27.90. ArriVent BioPharma has a 52 week low of $17.00 and a 52 week high of $35.83.

Hedge Funds Weigh In On ArriVent BioPharma

Hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of ArriVent BioPharma by 27.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company’s stock worth $40,000 after purchasing an additional 438 shares in the last quarter. Wellington Management Group LLP lifted its position in ArriVent BioPharma by 0.7% during the fourth quarter. Wellington Management Group LLP now owns 82,278 shares of the company’s stock worth $1,655,000 after purchasing an additional 532 shares during the period. Woodline Partners LP grew its stake in ArriVent BioPharma by 0.4% during the first quarter. Woodline Partners LP now owns 146,373 shares of the company’s stock worth $2,706,000 after buying an additional 576 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in ArriVent BioPharma by 4.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 14,743 shares of the company’s stock valued at $297,000 after buying an additional 585 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in shares of ArriVent BioPharma by 31.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock worth $56,000 after acquiring an additional 609 shares in the last quarter. Institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.